8-K/A XBRL

AMENDMENT NO. 1 TO FORM 8-K

Company: MoonLake Immunotherapeutics
Filed: May 16, 2022
Period of Report: April 5, 2022
Accession Number: 0001213900-22-027102

View Document ↗ View on SEC.gov ↗